| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BGJ398 | 872511-34-7 | sc-364430 sc-364430A sc-364430B sc-364430C | 5 mg 10 mg 50 mg 100 mg | $216.00 $252.00 $594.00 $1009.00 | 4 | |
A chemical compound known as an inhibitor of FGFR-4, a receptor tyrosine kinase involved in cell growth and development. By inhibiting FGFR-4, BGJ398 disrupts downstream signaling pathways related to cell proliferation and survival. This compound's inhibitory properties make it valuable for research, allowing scientists to study the role of FGFR-4 in cellular processes without mentioning specific clinical or therapeutic applications. | ||||||
Debio-1347 | 1265229-25-1 | sc-507386 | 10 mg | $324.00 | ||
Acts as an ATP-competitive inhibitor, binding to the ATP-binding pocket of FGFR-4, inhibiting its kinase activity and downstream signaling in cancer cells. | ||||||
AZD4547 | 1035270-39-3 | sc-364421 sc-364421A | 5 mg 10 mg | $198.00 $309.00 | 6 | |
Inhibits FGFR-4 by competing with ATP for binding to its kinase domain, leading to inhibition of FGFR-4 signaling and potential anti-cancer effects. | ||||||
AP 24534 | 943319-70-8 | sc-362710 sc-362710A | 10 mg 50 mg | $175.00 $983.00 | 2 | |
Acts as a multi-targeted kinase inhibitor, including FGFR-4, blocking its activity and interfering with cancer cell proliferation and angiogenesis. | ||||||
Erdafitinib | 1346242-81-6 | sc-507388 | 10 mg | $138.00 | ||
Selectively targets FGFR-4, inhibiting its kinase activity and downstream signaling, potentially leading to therapeutic benefits in FGFR-4-driven cancers. | ||||||